Revised: October 2015
SUMMARY OF PRODUCT CHARACTERISTICS
NAME OF THE VETERINARY MEDICINAL PRODUCT
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single dose of the vaccine vial contains:
Canine distemper virus, strain Onderstepoort ≥ 104.0 TCID50*
Canine adenovirus 2, strain Manhattan LPV3 ≥ 104.0 TCID50*
Canine parvovirus, strain 154 ≥ 107.0 TCID50*
*Tissue culture infective dose 50%
For full list of excipients, see section 6.1.
Lyophilisate for suspension for injection.
Indications for use, specifying target species
For the active immunisation of dogs to reduce clinical signs of disease caused by canine distemper virus infection; to prevent clinical signs and viral excretion caused by canine parvovirus infection; to reduce clinical signs of canine contagious hepatitis and viral excretion due to canine adenovirus 1 infection and to reduce clinical signs of respiratory infection and viral excretion caused by adenovirus type 2 infection.
Onset of immunity: one week
Duration of immunity:three years.
4.4 Special warnings for each target species
The efficacy of the CDV, CAV2 and CPV components of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has been proved to be of benefit against virulent challenge in the presence of maternal antibody levels to CDV, CAV2 and CPV that are likely to be encountered under field conditions.
4.5 Special precautions for use, including special precautions to be taken by the person administering the medicinal product to animals
Special precautions for use in animals
Only healthy dogs should be vaccinated. Dogs should not be exposed to unnecessary risk of infection within the first 2 weeks after completion of the vaccination regimen.
While the canine parvovirus vaccine strain may be shed at very low levels for up to 8 days after inoculation, there is no evidence that this results in clinical symptoms if non-vaccinated animals are infected.
Special precautions to be taken by the person administering the medicinal product to animals
In the case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of package leaflet.
4.6 Adverse reactions (frequency and seriousness)
A common reaction after subcutaneous administration with the diluent provided is a diffuse swelling up to 5 mm in diameter at the site of injection. Occasionally this swelling may be hard and painful and last for up to 3 days post injection.
In rare cases a transient rise in body temperature and/or a transient acute hypersensitivity reaction (anaphylaxis) - with signs that may include lethargy, facial oedema, pruritus, dyspnoea, vomiting, diarrhoea or collapse - may occur shortly after vaccination.
4.7 Use during pregnancy and lactation
Can be used in pregnant bitches which have previously been vaccinated with the Canigen DHPPi, DHP, Parvo-C or Pi.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccines of the Canigen series against canine leptospirosis caused by all or some of the following serovars: L. interrogansserogroup Canicola serovar Canicola, L. interrogansserogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogansserogroup Australis serovar Bratislava, and L.kirschneriserogroup Grippotyphosa serovar Bananal/Liangguang.
After administration with one of the leptospirosis vaccines, a mild and transient increase in body temperature (≤ 1 °C) may occur for a few days after vaccination, with some pups showing less activity and/or a reduced appetite. A small transient swelling (≤ 4 cm), which can occasionally be firm and painful on palpation, may be observed at the site of injection. Any such swelling will either have disappeared or be clearly diminished by 14 days post-vaccination.
After mixed administration of an overdose of Canigen DHP and an overdose of the leptospirosis vaccines of the Canigen series, transient local reactions such as diffuse to firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no longer than 5 weeks, however some may take a little longer to completely disappear.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccine of the Canigen series against rabies. After administration with the rabies vaccine, where this product is authorised, transient local reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed for up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post dosing.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed, with the live vaccine for intranasal administration of the Canigen series against infectious tracheobronchitis caused by Bordetella bronchisepticaand/or canine parainfluenza virus.
When Canigen DHP is used with any of the other Canigen vaccines referred to above, the minimum vaccination age for each vaccine must be taken into account such that at the time of vaccination, the dogs are at or older than the oldest minimum vaccination age for the individual vaccines.
Consult product leaflets before administering products simultaneously.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
4.9 Amounts to be administered and administration route
The contents of one vial of reconstituted vaccine should be injected subcutaneously.
Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml) of the diluent provided or the vaccines of the Canigen series against rabies or leptospirosis as mentioned in section4.8 (where these products are authorised). Sterile equipment should be used for administration.
Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Primary course vaccination:
A single injection should establish active immunity in dogs of 10 weeks of age or older. Where earlier protection is required a first dose may be given to puppies from6 weeks of age, but because maternally derived passive antibody can interferewith the response to vaccination a final dose should be given 2 - 4 weeks later i.e. at 10 weeks of age or older.
To maintain protection a single booster dose is recommended every three years.
Overdose (symptoms, emergency procedures, antidotes)(if necessary)
No effects other than those given in section 4.6
ATCvet code: QI07AD02
The vaccine contains attenuated antigens to stimulate active immunity in dogs against canine distemper virus, canine parvovirus, canine contagious hepatitis caused by canine adenovirus 1 and respiratory disease caused by canine adenovirus type 2.
6.1 List of excipients
pancreatic digest of casein
di-Sodium phosphate 12 H2O
water for injections.
Do not mix with any other veterinary medicinal product except with the vaccines of the Canigen series as recommended in section 4.8.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 24 months.
Shelf life after reconstitution: 30 minutes.
6.4 Special precautions for storage
Store in a refrigerator (2 C - 8 C).
Do not freeze.
Protect from light.
Reconstituted vaccine: Store in a refrigerator at 2 C - 8 C with care being taken to avoid prolonged or repetitive exposure to high ambient temperature following withdrawal from the refrigerator prior to use.
6.5 Nature and composition of the immediate packaging
Clear, Glass Type I (Ph.Eur) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.
Cardboard or plastic box containing 10 or 50 single dose vials.
Not all presentations may be marketed.
6.6 Special precautions for disposal of unused veterinary medicinal product or waste material derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
MARKETING AUTHORISATION HOLDER
Intervet International BV
Intervet UK Ltd.
MARKETING AUTHORISATION NUMBER
DATE OF FIRST AUTHORISATION
21 April 2006
DATE OF REVISION OF THE TEXT
07 October 2015
Page 5 of 5